This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
BMC Neurology Open Access 11 July 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vicari, A., Ciceri, F., Folli, F. et al. Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 12, 441–442 (1998). https://doi.org/10.1038/sj.leu.2400915
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2400915
This article is cited by
-
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study
BMC Neurology (2013)
-
Mitoxantrone: benefits and risks in multiple sclerosis patients
Neurological Sciences (2009)
-
Acute myeloid leukemia induced by mitoxantrone treatment for aggressive multiple sclerosis
Neurological Sciences (2008)
-
Two new cases of acute promyelocytic leukemia following mitoxantrone treatment in patients with multiple sclerosis
Leukemia (2006)
-
Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with mitoxantrone
Leukemia (2004)